NCT06540066 - A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Advanced CancerAdvanced Solid TumorMetastatic CancerMetastatic Solid Tumor

Interventions

DRUG

BGB-B3227

Administered intravenously.

DRUG

Tislelizumab

Administered intravenously.

DRUG

Chemotherapy

Administered in accordance with relevant local guidelines and/or prescribing information.

Trial Locations (12)

20089

RECRUITING

Istituto Clinico Humanitas, Rozzano

20133

RECRUITING

Fondazione Irccs Istituto Nazionale Dei Tumori, Milan

20141

RECRUITING

Istituto Europeo Di Oncologia, Milan

78758

RECRUITING

Next Oncology, Austin

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

200032

RECRUITING

Affiliated Zhongshan Hospital of Fudan University, Shanghai

90089-1019

RECRUITING

Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles

63110-1010

RECRUITING

Washington University in St Louis, St Louis

07601-1915

RECRUITING

Hackensack University Medical Center, Hackensack

77030-3907

RECRUITING

Md Anderson Cancer Center, Houston

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli, Roma